Effects of Weight Loss on Nonalcoholic Fatty Liver Disease

ABSTRACT

Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases worldwide, affecting men, women, and children. This is due, in part, to the obesity epidemic, which is associated with increased prevalence of NAFLD. The NAFLD spectrum ranges from simple steatosis to nonalcoholic steatohepatitis (NASH), which is the potentially progressive form. NAFLD is associated with metabolic syndrome and insulin resistance. Treatment recommendations include weight reduction through both diet and physical activity, and weight-loss surgery for extreme obesity. Most medical regimens target components of the metabolic syndrome or oxidative stress associated with the pathogenesis of NASH. These include antiobesity regimens, insulin sensitizers, antihyperlipidemics, and antioxidants. Bariatric surgery is effective for achieving and maintaining weight loss and reversing the complications of metabolic syndrome. On the other hand, the literature lacks well-designed, randomized control trials that assess the efficacy of anti-obesity regimens on histologic and long-term outcomes of NAFLD.

KEYWORDS

Nonalcoholic fatty liver disease (NAFLD) - nonalcoholic steatohepatitis (NASH) - weight loss

REFERENCES

• 1 World Health Organization .Obesity and overweight. Available at: http://www.who.int/dietphysicalactivity/publications/facts/obesity/en/ Accessed December 10, 2007
• 2 Obesity Action Coalition .Obesity. Available at: http://www.obesityaction.org/aboutus/mission.php Accessed January 19, 2008
• 3 Centers for Disease Control and Prevention .Overweight and obesity. Available at: http://www.cdc.gov/nccdphp/dnpa/obesity/index.htm Accessed December 10, 2007
• 4 Bouneva I, Kirby D. Management of nonalcoholic fatty liver disease: weight control.  Clin Liver Dis. 2004;  8(3) 693-713
• 5 Centers for Disease Control and Prevention .Diabetes and trends. Available at: http://www.cdc.gov/diabetes/statistics/prev/national/figpersons.htm Accessed January 18, 2008
• 6 Wanless I R, Lentz J S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors.  Hepatology. 1990;  12 1106-1110
• 7 Ong J P, Younossi Z M. Epidemiology and natural history of NAFLD and NASH.  Clin Liver Dis. 2007;  11(1) 1-16
• 8 Ong J P, Pitts A, Younossi Z M. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease.  J Hepatol. 2008;  49 608-612
• 9 Solga S, Alkhuraishe A R, Clark J M et al.. Dietary composition and nonalcoholic fatty liver disease.  Dig Dis Sci. 2004;  49 1578-1583
• 10 Huang M A, Greenson J K, Chao C et al.. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study.  Am J Gastroenterol. 2005;  100 1072-1081
• 11 Hernandez R, Martinez-Lara E, Canuelo A et al.. Steatosis recovery after treatment with a balanced sunflower or olive oil-based diet: involvement of perisinusoidal stellate cells.  World J Gastroenterol. 2005;  11 7480-7485
• 12 Lanza-Jacoby S, Smythe C, Phetteplace H, Tabares A. Adaptation to a fish oil diet before inducing sepsis in rats prevents fatty infiltration of the liver.  JPEN J Parenter Enteral Nutr. 1992;  16 353-358
• 13 Lai H S, Lin W H, Chen P R, Wu H C, Lee P H, Chen W J. Effects of high-fiber diet on hepatocyte apoptosis and liver regeneration after partial hepatectomy in rats with fatty liver.  JPEN J Parenter Enteral Nutr. 2005;  29 401-407
• 14 Samaha F F, Iqbal N, Seshadri P et al.. A low-carbohydrate as compared with a low-fat diet in severe obesity.  N Engl J Med. 2003;  348 2074-2081
• 15 Stern L, Iqbal N, Seshadri P et al.. The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial.  Ann Intern Med. 2004;  140 778-785
• 16 Dansinger M L, Gleason J A, Griffith J L, Selker H P, Schaefer E J. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial.  JAMA. 2005;  293 43-53
• 17 Stewart K J, Bacher A C, Turner K et al.. Exercise and risk factors associated with metabolic syndrome in older adults.  Am J Prev Med. 2005;  28 9-18
• 18 Gauthier M S, Couturier K, Latour J G, Lavoie J M. Concurrent exercise prevents high-fat-diet-induced macrovesicular hepatic steatosis.  J Appl Physiol. 2003;  94 2127-2134
• 19 Ueno T, Sugawara H, Sujaku K et al.. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver.  J Hepatol. 1997;  27(1) 103-107
• 20 Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients.  Gastroenterology. 1990;  99(5) 1408-1413
• 21 Clark J M. Weight loss as a treatment for nonalcoholic fatty liver disease.  J Clin Gastroenterol. 2006;  40(suppl 1) S39-S43
• 22 Krempf M, Louvet J P, Allanic H et al.. Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity.  Int J Obes Relat Metab Disord. 2003;  27 591-597
• 23 Harrison S A, Fincke C, Helinski D et al.. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients.  Aliment Pharmacol Ther. 2004;  20 623-628
• 24 Hatzitolios A, Savopoulos C, Lazaraki G et al.. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia.  Indian J Gastroenterol. 2004;  23(4) 131-134
• 25 Sabuncu T, Nazligul Y, Karaoglanoglu M et al.. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis.  Rom J Gastroenterol. 2003;  12 189-192
• 26 Gary-Bobo M, Elachouri G, Gallas J F et al.. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats.  Hepatology. 2007;  46 122-129
• 27 Van Gaal L F, Rissanen A M, Scheen A J, Ziegler O, Rossner S. RIO-Europe Study Group . Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.  Lancet. 2005;  365 1389-1397
• 28 Kakafika A I, Mikhailidis D P, Karagiannis A, Athyros V G. The role of endocannabinoid system blockade in the treatment of the metabolic syndrome.  J Clin Pharmacol. 2007;  47(5) 642-652
• 29 Rucker D, Padwal R, Li S K, Curioni C, Lau D C. Long term pharmacotherapy for obesity and overweight: updated meta-analysis.  BMJ. 2007;  335(7631) 1194-1199
• 30 Dixon J B. Surgical treatment for obesity and its impact on non-alcoholic steatohepatitis.  Clin Liver Dis. 2007;  11(1) 141-154
• 31 Maggard M A, Shugarman L R, Suttorp M et al.. Meta-analysis: surgical treatment of obesity.  Ann Intern Med. 2005;  142(7) 547-559
• 32 Mun E C, Tavakkolizadeh A. Surgical management of severe obesity. Available at: http://www.utdol.com/utd/content/topic.do?topicKey=obesity/6916&selectedTitle=3~150&source=search_result Accessed January 20, 2008
• 33 Rucker Jr R D, Horstmann J, Schneider P D et al.. Comparisons between jejunoileal and gastric bypass operations for morbid obesity.  Surgery. 1982;  92(2) 241-249
• 34 Hocking M P, Davis G L, Franzini D A et al.. Long-term consequences after jejunoileal bypass for morbid obesity.  Dig Dis Sci. 1998;  43(11) 2493-2499
• 35 Kral J G, Thung S N, Biron S et al.. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis.  Surgery. 2004;  135(1) 48-58
• 36 Luyckx F H, Desaive C, Thiry A et al.. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty.  Int J Obes Relat Metab Disord. 1998;  22(3) 222-226
• 37 Silverman E M, Sapala J A, Appelman H D. Regression of hepatic steatosis in morbidly obese persons after gastric bypass.  Am J Clin Pathol. 1995;  104(1) 23-31
• 38 Mattar S G, Velcum L M, Rabinovitz M et al.. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome.  Ann Surg. 2005;  242(4) 610-617
• 39 Liu X, Laxenby A J, Clements R H, Jhala N, Abrams G A. Resolution of nonalcoholic steatohepatitis after gastric bypass surgery.  Obes Surg. 2007;  17 486-492
• 40 Clark J M, Alkhuraishi A R, Solga S F et al.. Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease.  Obes Res. 2005;  13(7) 1180-1186
• 41 Furuya Jr C K, de Oliveira C P, de Mello E S et al.. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years.  J Gastroenterol Hepatol. 2007;  22 510-514
• 42 Sjostrom L, Narbro K, Sjostrom D et al.. Effects of bariatric surgery on mortality in Swedish obese subjects.  N Engl J Med. 2007;  357 741-751
• 43 Dixon J B, Bhathal P S, Hughes N R, O'Brien P E. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss.  Hepatology. 2004;  39(6) 1647-1654
• 44 O'Brien P E, Dixon J B, Laurie C et al.. Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program: a randomized trial.  Ann Intern Med. 2006;  144(9) 625-633
• 45 Choudhury J, Sanyal A J. Clinical aspects of fatty liver disease.  Semin Liver Dis. 2004;  24 349-362
• 46 Hedley A A, Ogden C L, Johnson C L, Carroll M D, Curtin L R, Flegal K M. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999–2002.  JAMA. 2004;  291 2847-2850
• 47 Franzese A, Vajro P, Argenziano A et al.. Liver involvement in obese children: ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population.  Dig Dis Sci. 1997;  42 1428-1432
• 48 Tominaga K, Kurata J H, Chen Y K et al.. Prevalence of fatty liver in Japanese children and relationship to obesity: an epidemiological ultrasonographic survey.  Dig Dis Sci. 1995;  40 2002-2009
• 49 Nobili V, Marcellini M, Devito R et al.. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice.  Hepatology. 2006;  44(2) 458-465
• 50 Hickman I J, Clouston A D, Macdonald G A et al.. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C.  Gut. 2002;  51 89-94
• 51 Hickman I J, Jonsson J R, Prins J B et al.. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvement in alanine aminotransferases, fasting insulin and quality of life.  Gut. 2004;  53(3) 413-419